**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 76975

**Manuscript Type:** LETTER TO THE EDITOR

**Statistical proof of *Helicobacter pylori* eradication in preventing metachronous gastric cancer after endoscopic resection in an East Asian population**

Karbalaei M *et al*. *H. pylori* eradication and risk of MGC

Mohsen Karbalaei, Masoud Keikha

**Mohsen Karbalaei,** Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft 78617-56447, Iran

**Masoud Keikha,** Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 13131-99137, Iran

**Author contributions:** Karbalaei M and Keikha M contributed to conceptualization, data curation, original drafting, and manuscript review & editing; all authors critically reviewed and approved the final version of the manuscript before submitting.

**Corresponding author: Masoud Keikha, PhD, Doctor, Instructor, Teaching Assistant,** Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Vakilabad Blvd., Bahonar Blvd. Pardis campus, Mashhad 13131-99137, Iran. masoud.keykha90@gmail.com

**Received:** April 8, 2022

**Revised:** May 29, 2022

**Accepted:** July 27, 2022

**Published online:** August 27, 2022

**Abstract**

We conducted a comprehensive literature review and meta-analysis study on the efficacy of *Helicobacter pylori* (*H. pylori*) eradication in preventing metachronous gastric cancer after endoscopic resection among an East Asian population. Our results showed that the eradication of this pathogen significantly reduced the risk of susceptibility to metachronous gastric cancer in these patients. However, based on the available evidence, several factors such as increasing age, severe atrophy in the corpus and antrum, and intestinal metaplasia all may increase the risk of metachronous gastric cancer in *H. pylori* eradicated patients.

**Key Words:** *Helicobacter pylori*; Gastric cancer; Eradication rate; Metachronous gastric cancer

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Karbalaei M, Keikha M. Statistical proof of *Helicobacter pylori* eradication in preventing metachronous gastric cancer after endoscopic resection in an East Asian population. *World J Gastrointest Surg* 2022; 14(8): 867-873

**URL:** https://www.wjgnet.com/1948-9366/full/v14/i8/867.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v14.i8.867

**Core Tip:** Gastrointestinal infections caused by *Helicobacter pylori* (*H. pylori*) is one of the most well-known infections in the human digestive tract. This bacterium successfully has been colonized in the stomach of more than 4 billion people worldwide. In many developing countries, these microorganisms are colonized in childhood, which in later years may develop to severe complications, particularly gastric adenocarcinoma. In the present study, we statistically evaluated the effectiveness of *H. pylori* eradication in reducing the risk of tend to metachronous gastric cancer (MGC) in Asian populations. Our results suggested that the eradication of this pathogen significantly reduced the risk of susceptibility to MGC in these patients. However, based on the available evidence, several factors such as increasing age, severe atrophy in the corpus and antrum, and intestinal metaplasia all may increase the risk of MGC in *H. pylori* extirpated patients. Unfortunately, there is no detailed information about the location of the stomach where the reduction of gastric cancer can be achieved after *H. pylori* eradication. Therefore, in future studies, more research should be done on the recent puzzle.

**TO THE EDITOR**

*Helicobacter pylori* (*H. pylori*) is a Gram-negative, microaerophilic, and helical microorganism that colonizes the gastric mucosa in half of the world’s population[1]. This bacterium is the main etiologic cause of gastritis, dyspepsia, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, gastric cancer, and peptic ulcer[1-3]. According to the literature, *H. pylori* also contributes in extragastrointestinal disorders such as insulin resistance, non-alcoholic liver disease, diabetes mellitus, coronary artery disease, and neurodegenerative disease[3,4]. In 1994, the International Agency for Research on Cancer (IARC) identified this bacterium as a group I gastric carcinogen[5]. There is ample evidence about the positive relationship between *H. pylori* infection and gastric cancer; primary infection with this bacterium has been proven to lead to cancer by inducing atrophic gastritis, intestinal metaplasia, and dysplasia[6]. According to previous randomized controlled trials (RCTs), it seems that the eradication of this pathogen is not effective in preventing the occurrence of primary gastric cancer[7-12]. Doorakkers *et al*[13] in a recent meta-analysis found that the eradication of this microorganism fundamentally reduced the incidence of primary gastric cancer.

Antrectomy (distal gastric resection) is a rare surgical procedure to treat early distal gastric cancer, in which the pyloric antrum is excised; although the presence of *H. pylori* may be decreased in the residual stomach, both untreated bacterial infection and biliopancreatic reflux damage the residual gastric mucosa, which can be considered as precursors for gastric stump cancer (GSC)[14]. Endoscopic resection (ER) procedures such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are known as accepted therapeutic strategies for treating early gastric cancer (EGC); although the effect of ER on EGC treatment is greater than that of gastrectomy, the risk of metachronous gastric lesions in the remnant stomach is higher after ER than gastrectomy[15].

Based on documents, the incidence of metachronous gastric cancer (MGC) has been estimated at 2.7%-15.6% in 3-5 years after EGC[16]. The efficacy of eradication of infection in the prevention of metachronous recurrence is controversial[15,17]. In the present study, we determined the beneficial effect of *H. pylori* eradication to prevent the recurrence of MGC after ER in an East Asian population.

We searched scientific databases such as Scopus, PubMed, Google Scholar, Cochrane Library, as well as Embase regardless of restriction in date and language by November 2020. The titles and abstracts of all papers were assessed to select the relevant articles. Then, eligible studies related to the effect of definitive treatment of infectionon the recurrence of MGC after ER were collected. The inclusion criteria were: (1) RCTs or cohort studies on the effect of standard bacterial eradication on metachronous recurrence; (2) comparative studies of people with conventional *H. pylori* eradication and those who do not receive conventional eradication procedure; and (3) studies on the East Asian population. On the other hand, criteria such as (1) review articles, letters, or congress abstracts; (2) duplication studies; (3) non-clinical studies; and (4) studies with insufficient materials and findings were considered as the exclusion criteria. We collected the essential information using Comprehensive Meta-Analysis software, version 2.2. The incidence of metachronous recurrence was reported in each group as a percentage with 95% confidence interval (95%CI). Moreover, the clinical achievement of *H*. *pylori* eradication in reduction of metachronous recurrence was also measured using odds ratio (OR) with 95%CI. Heterogeneity was determined *via* *I2* value and Cochran’s *Q* test; a random-effect model was applied in high heterogeneity cases (*I2* > 25% and Cochran’s-*Q* *P* > 0.05) according to the Dersimonian and Laird method. The potential study bias was assessed by the Egger’s test and Begg’s test[18,19].

A total of 1753 documents were retrieved during the initial literature search. Finally, we selected 23 articles as eligible articles according to the inclusion criteria[20-42]. The demographic information such as first author, date of publication, country, follow-up years, metachronous lesions, frequency of metachronous recurrence in both eradicated and persistent cases, and references are summarized in Table 1. These studies were conducted during 1997-2019. Of all the studies, 10 were from Korea, and 10 from the Japan. In the current analysis, we evaluated the data of 9233 *H. pylori* positive cases to determine the efficacy of complete eradication in preventing metachronous events.

The frequency of metachronous recurrence in both *H. pylori* extirpated and persistently infected cases was 7.2% (95%CI: 6.4-8.1, *P* = 0.01; *I2* = 81.68, *Q* = 125.56, *P* = 0.01; Egger’s *P* = 0.08, Begg’s *P* = 0.05) and 17.7% (95%CI: 16.1-19.5, *P* = 0.01; *I2* = 92.68, *Q* = 314.26, *P* = 0.01; Egger’s *P* = 0.01, Begg’s *P* = 0.54), respectively.

According to the statistical analysis, there is an inverse relation between *H. pylori* elimination and metachronous recurrence (OR = 0.53, 95%CI: 0.44-0.65, *P* = 0.01; *I2* = 39.22, *Q* = 34.55, *P* = 0.03; Egger’s *P* = 0.08, Begg’s *P* = 0.09). We showed that the eradication of *H. pylori* can significantly reduce the risk of metachronous recurrence (Figure 1).

Although most of included studies had not investigated the positive effect of *H. pylori* eradication in reducing MGC in each location of the stomach, in patients with *H. pylori* eradication, the risk of MGC was significantly associated with other conditions such as severity of corpus atrophy and intestinal metaplasia[21-23,27,39,40]. However, Han *et al*[39] showed that antrum/body atrophy and old age can meaningfully increase the risk of metachronous cancer after *H. pylori* eradication[24]. In some studies, there was no significant relationship between this cancer and the eradication of *H. pylori*[26,31,36].

Gastric cancer is one of the most prevalent cancers worldwide, especially in East Asian countries; today, the incidence of secondary gastric cancer after ER has become a major public health concern[34]. Unfortunately, in some cases, the eradication of *H. pylori* has not been able to prevent MGC in patients with ER. In general, the clinical eradication of *H. pylori* seems to be effective in preventing secondary gastric cancer and improving quality of life and survival of patients with gastric cancer[43]. In the present study, using data from 9233 *H. pylori* positive cases, we showed an inverse association between the elimination of *H. pylori* and progression to MGC in patients with a record of ER. In previous studies, we have shown that eradicating *H. pylori* in patients with gastric ulcers can reduce the risk of gastric cancer[44]. In general, it is suggested that eradicating *H. pylori* after primary gastric cancer can reduce the risk of MGC and increase survival in gastric cancer population[15,34,45].

Unfortunately, there is no detailed information about the location of the stomach where the reduction of gastric cancer can be achieved after *H. pylori* eradication. Therefore, in future studies, more research should be done on the recent puzzle.

**REFERENCES**

1 **Ansari S**, Yamaoka Y. Role of vacuolating cytotoxin A in *Helicobacter pylori* infection and its impact on gastric pathogenesis. *Expert Rev Anti Infect Ther* 2020; **18**: 987-996 [PMID: 32536287 DOI: 10.1080/14787210.2020.1782739]

2 **Youssefi M**, Tafaghodi M, Farsiani H, Ghazvini K, Keikha M. Helicobacter pylori infection and autoimmune diseases; Is there an association with systemic lupus erythematosus, rheumatoid arthritis, autoimmune atrophy gastritis and autoimmune pancreatitis? A systematic review and meta-analysis study. *J Microbiol Immunol Infect* 2021; **54**: 359-369 [PMID: 32891538 DOI: 10.1016/j.jmii.2020.08.011]

3 **Mladenova I**. Clinical Relevance of Helicobacter pylori Infection. *J Clin Med* 2021; **10**: 3473

4 **Lee S**, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: A systematic review and meta-analysis. *J Am Acad Dermatol* 2019; **80**: 466-477.e16 [PMID: 30031145 DOI: 10.1016/j.jaad.2018.07.013]

5 . Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. *IARC Monogr Eval Carcinog Risks Hum* 1994; **61**: 1-241 [PMID: 7715068]

6 **Keikha M**, Karbalaei M. EPIYA motifs of *Helicobacter pylori cagA* genotypes and gastrointestinal diseases in the Iranian population: a systematic review and meta-analysis. *New Microbes New Infect* 2021; **41**: 100865 [PMID: 33912350 DOI: 10.1016/j.nmni.2021.100865]

7 **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

8 **Dinis-Ribeiro M**, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; MAPS Participants; European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Virchows Arch* 2012; **460**: 19-46 [PMID: 22190006 DOI: 10.1007/s00428-011-1177-8]

9 **Ma JL**, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF Jr, You WC, Gail MH. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. *J Natl Cancer Inst* 2012; **104**: 488-492 [PMID: 22271764 DOI: 10.1093/jnci/djs003]

10 **Kato M**. Metachronous gastric cancer risk after endoscopic resection of early gastric cancer and H. pylori status. *J Gastroenterol* 2019; **54**: 478-479 [PMID: 30770974 DOI: 10.1007/s00535-019-01560-2]

11 **Lee YC**, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. *Gut* 2013; **62**: 676-682 [PMID: 22698649 DOI: 10.1136/gutjnl-2012-302240]

12 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

13 **Doorakkers E**, Lagergren J, Engstrand L, Brusselaers N. *Helicobacter pylori* eradication treatment and the risk of gastric adenocarcinoma in a Western population. *Gut* 2018; **67**: 2092-2096 [PMID: 29382776 DOI: 10.1136/gutjnl-2017-315363]

14 **Basso L**, Gallo G, Biacchi D, Carati MV, Cavallaro G, Esposito L, Giuliani A, Izzo L, Izzo P, Lamazza A, Polistena A, Tarallo M, Micarelli A, Fiori E. Role of New Anatomy, Biliopancreatic Reflux, and Helicobacter Pylori Status in Postgastrectomy Stump Cancer. *J Clin Med* 2022; **11** [PMID: 35329824 DOI: 10.3390/jcm11061498]

15 **Xiao S**, Li S, Zhou L, Jiang W, Liu J. Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis. *J Gastroenterol* 2019; **54**: 226-237 [PMID: 30251121 DOI: 10.1007/s00535-018-1513-8]

16 **Abe S**, Oda I, Minagawa T, Sekiguchi M, Nonaka S, Suzuki H, Yoshinaga S, Bhatt A, Saito Y. Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric Cancer. *Clin Endosc* 2018; **51**: 253-259 [PMID: 28920420 DOI: 10.5946/ce.2017.104]

17 **Jung DH**, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC. Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis. *PLoS One* 2015; **10**: e0124725 [PMID: 25915048 DOI: 10.1371/journal.pone.0124725]

18 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188

19 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

20 **Uemura N**, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. *Gastroenterol Clin North Am* 2000; **29**: 819-827 [PMID: 11190066 DOI: 10.1016/s0889-8553(05)70149-7]

21 **Nakagawa S**, Asaka M, Kato M, Nakamura T, Kato C, Fujioka T, Tatsuta M, Keida K, Terao S, Takahashi S. Helicobacter pylori eradication and metachronous gastric cancer after endoscopic mucosal resection of early gastric cancer. *Aliment Pharm Therap* 2006; **24**: 214-218

22 **Fukase K**, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M; Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 2008; **372**: 392-397 [PMID: 18675689 DOI: 10.1016/S0140-6736(08)61159-9]

23 **Shiotani A**, Uedo N, Iishi H, Yoshiyuki Y, Ishii M, Manabe N, Kamada T, Kusunoki H, Hata J, Haruma K. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. *Digestion* 2008; **78**: 113-119 [PMID: 19023205 DOI: 10.1159/000173719]

24 **Han JS**, Jang JS, Choi SR, Kwon HC, Kim MC, Jeong JS, Kim SJ, Sohn YJ, Lee EJ. A study of metachronous cancer after endoscopic resection of early gastric cancer. *Scand J Gastroentero* 2011; **46**: 1099-1104

25 **Kim HJ**, Hong SJ, Ko BM, Cho WY, Cho JY, Lee JS, Lee MS. Helicobacter pylori eradication suppresses metachronous gastric cancer and cyclooxygenase-2 expression after endoscopic resection of early gastric cancer. *The Korean J of Helicobacter and Upper Gastrointest Res* 2011; **11**: 117-123

26 **Maehata Y**, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H, Kanda M, Hirahashi M, Matsumoto T. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. *Gastrointest Endosc* 2012; **75**: 39-46 [PMID: 22018552 DOI: 10.1016/j.gie.2011.08.030]

27 **Watari J**, Moriichi K, Tanabe H, Kashima S, Nomura Y, Fujiya M, Tomita T, Oshima T, Fukui H, Miwa H, Das KM, Kohgo Y. Biomarkers predicting development of metachronous gastric cancer after endoscopic resection: an analysis of molecular pathology of Helicobacter pylori eradication. *Int J Cancer* 2012; **130**: 2349-2358 [PMID: 21732341 DOI: 10.1002/ijc.26275]

28 **Zhao B**, Zhang J, Mei D, Luo R, Lu H, Xu H, Huang B. Does Helicobacter pylori Eradication Reduce the Incidence of Metachronous Gastric Cancer After Curative Endoscopic Resection of Early Gastric Cancer: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2020; **54**: 235-241 [PMID: 30829904 DOI: 10.1097/MCG.0000000000001195]

29 **Kim YI**, Choi IJ, Kook MC, Cho SJ, Lee JY, Kim CG, Ryu KW, Kim YW. The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. *Helicobacter* 2014; **19**: 194-201 [PMID: 24612125 DOI: 10.1111/hel.12116]

30 **Bae SE**, Jung HY, Kang J, Park YS, Baek S, Jung JH, Choi JY, Kim MY, Ahn JY, Choi KS, Kim DH, Lee JH, Choi KD, Song HJ, Lee GH, Kim JH. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. *Am J Gastroenterol* 2014; **109**: 60-67 [PMID: 24343545 DOI: 10.1038/ajg.2013.404]

31 **Choi J**, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, Jung HC. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. *Clin Gastroenterol H* 2014; **12**: 793-800

32 **Kwon YH**, Heo J, Lee HS, Cho CM, Jeon SW. Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. *Aliment Pharmacol Ther* 2014; **39**: 609-618 [PMID: 24461252 DOI: 10.1111/apt.12633]

33 **Jung S**, Park CH, Kim EH, Shin SJ, Chung H, Lee H, Park JC, Shin SK, Lee YC, Lee SK. Preventing metachronous gastric lesions after endoscopic submucosal dissection through H elicobacter pylori eradication. *J Gastroenterol H* 2015; **30**: 75-81

34 **Yoon SB**, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. *Helicobacter* 2014; **19**: 243-248 [PMID: 25056262 DOI: 10.1111/hel.12146]

35 **Kim SB**, Lee SH, Bae SI, Jeong YH, Sohn SH, Kim KO, Jang BI, Kim TN. Association between *Helicobacter pylori* status and metachronous gastric cancer after endoscopic resection. *World J Gastroenterol* 2016; **22**: 9794-9802 [PMID: 27956803 DOI: 10.3748/wjg.v22.i44.9794]

36 **Ami R**, Hatta W, Iijima K, Koike T, Ohkata H, Kondo Y, Ara N, Asanuma K, Asano N, Imatani A, Shimosegawa T. Factors Associated With Metachronous Gastric Cancer Development After Endoscopic Submucosal Dissection for Early Gastric Cancer. *J Clin Gastroenterol* 2017; **51**: 494-499 [PMID: 27505404 DOI: 10.1097/MCG.0000000000000620]

37 **Kwon Y**, Jeon S, Nam S, Shin I. Helicobacter pylori infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection. *Aliment Pharmacol Ther* 2017; **46**: 758-767 [PMID: 28799258 DOI: 10.1111/apt.14263]

38 **Chung CS**, Woo HS, Chung JW, Jeong SH, Kwon KA, Kim YJ, Kim KO, Park DK. Risk Factors for Metachronous Recurrence after Endoscopic Submucosal Dissection of Early Gastric Cancer. *J Korean Med Sci* 2017; **32**: 421-426 [PMID: 28145644 DOI: 10.3346/jkms.2017.32.3.421]

39 **Han SJ**, Kim SG, Lim JH, Choi JM, Oh S, Park JY, Kim J, Kim JS, Jung HC. Long-Term Effects of *Helicobacter pylori* Eradication on Metachronous Gastric Cancer Development. *Gut Liver* 2018; **12**: 133-141 [PMID: 29069890 DOI: 10.5009/gnl17073]

40 **Choi IJ**, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. *N Engl J Med* 2018; **378**: 1085-1095 [PMID: 29562147 DOI: 10.1056/NEJMoa1708423]

41 **Okada K**, Suzuki S, Naito S, Yamada Y, Haruki S, Kubota M, Nakajima Y, Shimizu T, Ando K, Uchida Y, Hirasawa T, Fujisaki J, Tsuchida T. Incidence of metachronous gastric cancer in patients whose primary gastric neoplasms were discovered after Helicobacter pylori eradication. *Gastrointest Endosc* 2019; **89**: 1152-1159.e1 [PMID: 30825537 DOI: 10.1016/j.gie.2019.02.026]

42 **Yamamoto K**, Kato M, Takahashi M, Haneda M, Shinada K, Nishida U, Yoshida T, Sonoda N, Ono S, Nakagawa M, Mori Y, Nakagawa S, Mabe K, Shimizu Y, Moriya J, Kubota K, Matsuno Y, Shimoda T, Watanabe H, Asaka M. Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. *Helicobacter* 2011; **16**: 210-216 [PMID: 21585606 DOI: 10.1111/j.1523-5378.2011.00833.x]

43 **Romero-Gallo J**, Harris EJ, Krishna U, Washington MK, Perez-Perez GI, Peek RM. Effect of Helicobacter pylori eradication on gastric carcinogenesis. *Lab Invest* 2008; **88**: 328-336

44 **Keikha M**. The association between Helicobacter pylori eradication in peptic ulcer patients and gastric cancer? Investigation in an East-Asian population. *Trends in Pharmacol Sci* 2020; **6**: 279-282

45 **Sugimoto M**, Murata M, Yamaoka Y. Chemoprevention of gastric cancer development after *Helicobacter pylori* eradication therapy in an East Asian population: Meta-analysis. *World J Gastroenterol* 2020; **26**: 1820-1840 [PMID: 32351296 DOI: 10.3748/wjg.v26.i15.1820]

**Footnotes**

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 8, 2022

**First decision:** May 11, 2022

**Article in press:** July 27, 2022

**Specialty type:** Infectious diseases

**Country/Territory of origin:** Iran

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Basso L, Italy; Cheng H, China; Cheng H, China; Mba IE, Nigeria **S-Editor:** Chen YL **L-Editor:** Wang TQ **P-Editor:** Chen YL

**Figure Legends**



**Figure 1** **Forest plot for incidence of metachronous gastric cancer between *Helicobacter pylori*-eradicated group and non-eradicated group in 23 studies.** 95%CI: 95% confidence interval.

**Table 1 Characteristics of included studies**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Country** | **Year** | **Follow-up years** | **Metachronous lesions** | ***H. Pylori* positive samples** | **Frequency** | **Mean age (yr)** | **Gender** | **Antrum/body/cardia** | **Ref.** |
| **Eradicated** | **Persistent** | **Eradicated** | **Persistent** | **Eradicated (M/F)** | **Persistent (M/F)** | **Eradicated** | **Persistent** |
| Uemura | Japan | 1997 | 3 years | EGC | 132 | 1/65 | 6/67 | 69.4 | 68.7 | 47/18 | 49/18 | 48/24/3 | 42/31/2 | [20] |
| Nakagawa | Japan | 2006 | 2 years | EGC | 2825 | 8/356 | 129/2469 | NA | NA | NA | NA | NA | NA | [21] |
| Fukase | Japan | 2008 | 3 years | EGC | 505 | 9/255 | 24/250 | 68 | 69 | 195/60 | 191/59 | 130/96/29 | 114/103/33 | [22] |
| Shiotani | Japan | 2008 | 24-48 mo | EGC | 91 | 9/80 | 1/11 | 66 | 82/18 | NA | NA | [23] |
| Han | Korea | 2011 | 18-57 mo | EGC | 116 | 4/94 | 2/22 | 70 | NA | NA | NA | NA | [24] |
| Kim | Korea | 2011 | 60 mo | EGC | 55 | 0/28 | 5/27 | 62 | 60 | 19/10 | 17/9 | 14/10/4 | 15/7/5 | [25] |
| Maehata | Japan | 2012 | 3 years | EGC | 268 | 15/177 | 13/91 | 68 | 72 | 128/49 | 66/25 | 70/91/16 | 34/48/9 | [26] |
| Watari | Japan | 2012 | 1 year | ER | 185 | 3/79 | 10/106 | NA | NA | NA | NA | NA | NA | [27] |
| Seo | Japan | 2012 | 27 mo | EGC | 74 | 0/61 | 0/13 | NA | NA | NA | NA | NA | NA | [28] |
| Kim | Korea | 2014 | 12 mo | EGC | 156 | 2/49 | 16/107 | 59 | 64 | 39/10 | 73/34 | 39/7/3 | 90/12/5 | [29] |
| Bae | Korea | 2014 | 60 mo | EGC/dysplasia | 667 | 34/485 | 24/182 | 62 | 64 | 380/105 | 145/37 | NA | NA | [30] |
| Choi | Korea | 2014 | 36 mo | EGC | 880 | 10/439 | 17/441 | 59 | 61 | 291/148 | 305/136 | 325/101/13 | 313/113/15 | [31] |
| Kwon | Korea | 2014 | 3 years | EGC | 283 | 10/214 | 10/69 | 61 | 60 | 141/73 | 49/20 | 197/10/7 | 63/4/2 | [32] |
| Jung | Korea | 2015 | 42 mo | EGC/dysplasia | 675 | 10/169 | 21/506 | NA | NA | NA | NA | NA | NA | [33] |
| Jeong | Korea | 2015 | NA | EGC | 148 | 3/88 | 2/60 | NA | NA | NA | NA | NA | NA | [34] |
| Kim | Korea | 2016 | 30 mo | EGC | 162 | 3/120 | 1/42 | 64 | 67 | 86/34 | 29/13 | 75/35/10 | 23/14/5 | [35] |
| Ami | Japan | 2017 | 53 mo | EGC | 226 | 0/212 | 0/14 | 69 | NA | NA | NA | NA | [36] |
| Kwon | Korea | 2017 | 47 mo | EGC/dysplasia | 395 | 33/368 | 8/27 | NA | NA | NA | NA | NA | NA | [37] |
| Chung | Korea | 2017 | 61 mo | EGC/dysplasia | 185 | 17/167 | 7/18 | 67 | NA | NA | NS | NA | [38] |
| Han | Korea | 2017 | 60 mo | EGC | 408 | 12/212 | 18/196 | 61 | 61 | 165/47 | 144/52 | 133/70/9 | 136/50/10 | [39] |
| Choi | Korea | 2018 | 5.9 years | EGC | 396 | 14/194 | 27/202 | 59 | 59 | 141/53 | 157/45 | 160/25/9 | 166/27/9 | [40] |
| Okada | Japan | 2019 | 2 years | ESD | 348 | 27/174 | 33/174 | 65 | 65 | 129/45 | 133/41 | 45/66/68 | 49/66/64 | [41] |
| Yamamoto | Japan | 2019 | 31.7 mo | Dysplasia | 53 | 12/17 | 15/36 | 67 | 67 | 14/3 | 28/8 | 6/11/1 | 15/18/3 | [42] |

ESD: Endoscopic submucosal dissection; EGC: Early gastric cancer; ER: Endoscopic resection; *H. pylori*: *Helicobacter pylori*; NA: Not available.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**